Vielight Inc

Vielight Inc manufactures photobiomodulation (PBM) devices for consumer and clinical use, specializing in transcranial and intranasal light therapy systems targeting brain health and systemic wellness. The company's core technology uses safe, non-ionizing red and near-infrared light energy to stimulate mitochondrial ATP production, with applications in cognitive enhancement, neurological conditions, and immune support. Product lines include the Neuro series (Pro 2, Duo, Gamma, Alpha variants) for brain photobiomodulation targeting Alzheimer's disease, traumatic brain injury, Parkinson's disease, mild cognitive impairment, autism, and PTSD; the Vagus device for non-invasive vagal nerve stimulation; the MIP for systemic wellness and immunity; and the X-Plus for thymus stimulation. Vielight has published 30+ peer-reviewed studies in collaboration with leading institutions including UCSF, Harvard, University of Toronto, Boston University, and University of Utah, with 20+ ongoing clinical trials and 800+ research participants. The company holds Health Canada medical device approval and conducts FDA-regulated clinical studies. Devices are marketed directly to consumers, practitioners, athletes, and military/veteran populations. Manufacturing and logistics are based in Hayward, California; administration in Toronto, Ontario; and a USA sales office in Shepherdstown, West Virginia. Over 100,000 devices sold globally with a 4.8/5 customer rating.